IBDEI1I6 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,24309,1,4,0)
;;=4^E11.40
;;^UTILITY(U,$J,358.3,24309,2)
;;=^5002644
;;^UTILITY(U,$J,358.3,24310,0)
;;=E11.51^^82^1051^11
;;^UTILITY(U,$J,358.3,24310,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,24310,1,3,0)
;;=3^DM Type 2 w/ Diab Periph Angiopathy w/o Gangrene
;;^UTILITY(U,$J,358.3,24310,1,4,0)
;;=4^E11.51
;;^UTILITY(U,$J,358.3,24310,2)
;;=^5002650
;;^UTILITY(U,$J,358.3,24311,0)
;;=E11.52^^82^1051^10
;;^UTILITY(U,$J,358.3,24311,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,24311,1,3,0)
;;=3^DM Type 2 w/ Diab Periph Angiopathy w/ Gangrene
;;^UTILITY(U,$J,358.3,24311,1,4,0)
;;=4^E11.52
;;^UTILITY(U,$J,358.3,24311,2)
;;=^5002651
;;^UTILITY(U,$J,358.3,24312,0)
;;=E11.620^^82^1051^4
;;^UTILITY(U,$J,358.3,24312,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,24312,1,3,0)
;;=3^DM Type 2 w/ Diab Dermatitis
;;^UTILITY(U,$J,358.3,24312,1,4,0)
;;=4^E11.620
;;^UTILITY(U,$J,358.3,24312,2)
;;=^5002655
;;^UTILITY(U,$J,358.3,24313,0)
;;=I10.^^82^1052^1
;;^UTILITY(U,$J,358.3,24313,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,24313,1,3,0)
;;=3^Essential/Primary Hypertension
;;^UTILITY(U,$J,358.3,24313,1,4,0)
;;=4^I10.
;;^UTILITY(U,$J,358.3,24313,2)
;;=^5007062
;;^UTILITY(U,$J,358.3,24314,0)
;;=I11.0^^82^1052^12
;;^UTILITY(U,$J,358.3,24314,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,24314,1,3,0)
;;=3^Hypertensive Heart Disease w/ Heart Failure
;;^UTILITY(U,$J,358.3,24314,1,4,0)
;;=4^I11.0
;;^UTILITY(U,$J,358.3,24314,2)
;;=^5007063
;;^UTILITY(U,$J,358.3,24315,0)
;;=I11.9^^82^1052^13
;;^UTILITY(U,$J,358.3,24315,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,24315,1,3,0)
;;=3^Hypertensive Heart Disease w/o Heart Failure
;;^UTILITY(U,$J,358.3,24315,1,4,0)
;;=4^I11.9
;;^UTILITY(U,$J,358.3,24315,2)
;;=^5007064
;;^UTILITY(U,$J,358.3,24316,0)
;;=I12.0^^82^1052^5
;;^UTILITY(U,$J,358.3,24316,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,24316,1,3,0)
;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
;;^UTILITY(U,$J,358.3,24316,1,4,0)
;;=4^I12.0
;;^UTILITY(U,$J,358.3,24316,2)
;;=^5007065
;;^UTILITY(U,$J,358.3,24317,0)
;;=I12.9^^82^1052^4
;;^UTILITY(U,$J,358.3,24317,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,24317,1,3,0)
;;=3^Hypertensive CKD w/ Stage 1-4 CKD
;;^UTILITY(U,$J,358.3,24317,1,4,0)
;;=4^I12.9
;;^UTILITY(U,$J,358.3,24317,2)
;;=^5007066
;;^UTILITY(U,$J,358.3,24318,0)
;;=I13.0^^82^1052^8
;;^UTILITY(U,$J,358.3,24318,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,24318,1,3,0)
;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD
;;^UTILITY(U,$J,358.3,24318,1,4,0)
;;=4^I13.0
;;^UTILITY(U,$J,358.3,24318,2)
;;=^5007067
;;^UTILITY(U,$J,358.3,24319,0)
;;=I13.10^^82^1052^10
;;^UTILITY(U,$J,358.3,24319,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,24319,1,3,0)
;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD
;;^UTILITY(U,$J,358.3,24319,1,4,0)
;;=4^I13.10
;;^UTILITY(U,$J,358.3,24319,2)
;;=^5007068
;;^UTILITY(U,$J,358.3,24320,0)
;;=I13.11^^82^1052^11
;;^UTILITY(U,$J,358.3,24320,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,24320,1,3,0)
;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD
;;^UTILITY(U,$J,358.3,24320,1,4,0)
;;=4^I13.11
;;^UTILITY(U,$J,358.3,24320,2)
;;=^5007069
;;^UTILITY(U,$J,358.3,24321,0)
;;=I13.2^^82^1052^9
;;^UTILITY(U,$J,358.3,24321,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,24321,1,3,0)
;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1I6 3797 printed Sep 23, 2025@19:45:12 Page 2
IBDEI1I6 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,24309,1,4,0)
+2 ;;=4^E11.40
+3 ;;^UTILITY(U,$J,358.3,24309,2)
+4 ;;=^5002644
+5 ;;^UTILITY(U,$J,358.3,24310,0)
+6 ;;=E11.51^^82^1051^11
+7 ;;^UTILITY(U,$J,358.3,24310,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,24310,1,3,0)
+10 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/o Gangrene
+11 ;;^UTILITY(U,$J,358.3,24310,1,4,0)
+12 ;;=4^E11.51
+13 ;;^UTILITY(U,$J,358.3,24310,2)
+14 ;;=^5002650
+15 ;;^UTILITY(U,$J,358.3,24311,0)
+16 ;;=E11.52^^82^1051^10
+17 ;;^UTILITY(U,$J,358.3,24311,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,24311,1,3,0)
+20 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/ Gangrene
+21 ;;^UTILITY(U,$J,358.3,24311,1,4,0)
+22 ;;=4^E11.52
+23 ;;^UTILITY(U,$J,358.3,24311,2)
+24 ;;=^5002651
+25 ;;^UTILITY(U,$J,358.3,24312,0)
+26 ;;=E11.620^^82^1051^4
+27 ;;^UTILITY(U,$J,358.3,24312,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,24312,1,3,0)
+30 ;;=3^DM Type 2 w/ Diab Dermatitis
+31 ;;^UTILITY(U,$J,358.3,24312,1,4,0)
+32 ;;=4^E11.620
+33 ;;^UTILITY(U,$J,358.3,24312,2)
+34 ;;=^5002655
+35 ;;^UTILITY(U,$J,358.3,24313,0)
+36 ;;=I10.^^82^1052^1
+37 ;;^UTILITY(U,$J,358.3,24313,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,24313,1,3,0)
+40 ;;=3^Essential/Primary Hypertension
+41 ;;^UTILITY(U,$J,358.3,24313,1,4,0)
+42 ;;=4^I10.
+43 ;;^UTILITY(U,$J,358.3,24313,2)
+44 ;;=^5007062
+45 ;;^UTILITY(U,$J,358.3,24314,0)
+46 ;;=I11.0^^82^1052^12
+47 ;;^UTILITY(U,$J,358.3,24314,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,24314,1,3,0)
+50 ;;=3^Hypertensive Heart Disease w/ Heart Failure
+51 ;;^UTILITY(U,$J,358.3,24314,1,4,0)
+52 ;;=4^I11.0
+53 ;;^UTILITY(U,$J,358.3,24314,2)
+54 ;;=^5007063
+55 ;;^UTILITY(U,$J,358.3,24315,0)
+56 ;;=I11.9^^82^1052^13
+57 ;;^UTILITY(U,$J,358.3,24315,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,24315,1,3,0)
+60 ;;=3^Hypertensive Heart Disease w/o Heart Failure
+61 ;;^UTILITY(U,$J,358.3,24315,1,4,0)
+62 ;;=4^I11.9
+63 ;;^UTILITY(U,$J,358.3,24315,2)
+64 ;;=^5007064
+65 ;;^UTILITY(U,$J,358.3,24316,0)
+66 ;;=I12.0^^82^1052^5
+67 ;;^UTILITY(U,$J,358.3,24316,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,24316,1,3,0)
+70 ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
+71 ;;^UTILITY(U,$J,358.3,24316,1,4,0)
+72 ;;=4^I12.0
+73 ;;^UTILITY(U,$J,358.3,24316,2)
+74 ;;=^5007065
+75 ;;^UTILITY(U,$J,358.3,24317,0)
+76 ;;=I12.9^^82^1052^4
+77 ;;^UTILITY(U,$J,358.3,24317,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,24317,1,3,0)
+80 ;;=3^Hypertensive CKD w/ Stage 1-4 CKD
+81 ;;^UTILITY(U,$J,358.3,24317,1,4,0)
+82 ;;=4^I12.9
+83 ;;^UTILITY(U,$J,358.3,24317,2)
+84 ;;=^5007066
+85 ;;^UTILITY(U,$J,358.3,24318,0)
+86 ;;=I13.0^^82^1052^8
+87 ;;^UTILITY(U,$J,358.3,24318,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,24318,1,3,0)
+90 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD
+91 ;;^UTILITY(U,$J,358.3,24318,1,4,0)
+92 ;;=4^I13.0
+93 ;;^UTILITY(U,$J,358.3,24318,2)
+94 ;;=^5007067
+95 ;;^UTILITY(U,$J,358.3,24319,0)
+96 ;;=I13.10^^82^1052^10
+97 ;;^UTILITY(U,$J,358.3,24319,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,24319,1,3,0)
+100 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD
+101 ;;^UTILITY(U,$J,358.3,24319,1,4,0)
+102 ;;=4^I13.10
+103 ;;^UTILITY(U,$J,358.3,24319,2)
+104 ;;=^5007068
+105 ;;^UTILITY(U,$J,358.3,24320,0)
+106 ;;=I13.11^^82^1052^11
+107 ;;^UTILITY(U,$J,358.3,24320,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,24320,1,3,0)
+110 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD
+111 ;;^UTILITY(U,$J,358.3,24320,1,4,0)
+112 ;;=4^I13.11
+113 ;;^UTILITY(U,$J,358.3,24320,2)
+114 ;;=^5007069
+115 ;;^UTILITY(U,$J,358.3,24321,0)
+116 ;;=I13.2^^82^1052^9
+117 ;;^UTILITY(U,$J,358.3,24321,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,24321,1,3,0)
+120 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD
